Abstract
In patients undergoing allogeneic stem cell transplantation, conditioning regimens containing alemtuzumab instead of anti-thymocyte globulin (ATG) may result in an earlier platelet engraftment and a reduced number of platelet transfusions. We performed a retrospective, single-center, case-control study analyzing time to engraftment and transfusion needs using alemtuzumab in comparison with ATG as part of conditioning protocol. Median values for time to platelet engraftment, number of transfused platelet concentrates and number of transfused red cell concentrates were 12 versus 19.5 days (p < 0.001), 2 versus 14 (p < 0.001) and 6 versus 14.5 (p = 0.003) in the alemtuzumab and ATG group. Time to leukocyte engraftment did not differ with median 15 days in both groups. Patients in the ATG group showed a significant higher decrease in platelet count during conditioning (68 vs. 29 %, p = 0.001), leading to significant lower median platelet counts at the day of stem cell infusion (38 vs. 95.5 Gpt/l, p = 0.008), and higher values for median C-reactive protein after first antibody infusion (69.0 vs. 43.6 mg/l, p = 0.001) compared with alemtuzumab group. Test for significance was done by using Wilcoxon rank-sum test. Subgroup analysis co...Continue Reading
References
Feb 18, 1982·The New England Journal of Medicine·N K RamsayM E Nesbit
Oct 23, 1997·Bone Marrow Transplantation·A NaglerV R Deutsch
May 31, 2002·Blood·Suparno ChakrabartiDonald W Milligan
Oct 18, 2002·Blood·José A Pérez-SimónUNKNOWN Spanish and United Kingdom Collaborative Groups for Nonmyeloablative Transplantation
Mar 3, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Irit AviviStephen Mackinnon
May 27, 2005·British Journal of Haematology·Nicolaus KrögerUNKNOWN Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Gr
Sep 9, 2005·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Herman Waldmann, Geoff Hale
Sep 27, 2005·Bone Marrow Transplantation·G D MyersC M Bollard
Jan 18, 2006·Bone Marrow Transplantation·G JuliussonC Malm
Sep 15, 2007·British Journal of Haematology·Karl S PeggsUNKNOWN UK and Spanish Collaborative Groups
Nov 6, 2007·Bone Marrow Transplantation·O PenackL Uharek
Oct 23, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Julio DelgadoStephen Mackinnon
Apr 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Koen van BesienSergio Giralt
Aug 22, 2009·The Lancet Oncology·Jürgen FinkeUNKNOWN ATG-Fresenius Trial Group
Aug 28, 2009·Transplant Infectious Disease : an Official Journal of the Transplantation Society·S H ParkC-C Kim
Nov 10, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hartmut BertzJürgen Finke
Feb 19, 2010·The New England Journal of Medicine·Sherrill J SlichterSuzanne Granger
Jul 1, 2010·Blood·Ronjon ChakravertyStephen Mackinnon
Apr 6, 2011·Blood·Robert J SoifferMary Eapen
Jun 28, 2011·Expert Opinion on Biological Therapy·Xavier Poiré, Koen van Besien
Aug 11, 2012·Lancet·Hannes WandtUNKNOWN Study Alliance Leukemia
Mar 7, 2013·Annals of Hematology·Christoph BusemannWilliam H Krüger
May 10, 2013·The New England Journal of Medicine·Simon J StanworthUNKNOWN TOPPS Investigators
May 15, 2015·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·A CumpelikD Zecher